plecanatide

A uroguanylin analog and guanylate cyclase (GC-C receptor) agonist that activates receptors on gut epithelial cells to maintain barrier function, mucus production, and suppress inflammation. It is used in the treatment of chronic idiopathic constipation and other gastrointestinal disorders.

Also Known As:

SP-304; Trulance; L-leucine, L-asparaginyl-L-alpha-aspartyl-L-alpha-glutamyl-L-cysteinyl-L-alpha-glutamyl-L-leucyl-L-cysteinyl-L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-, cyclic (4-12),(7-15)-bis(disulfide)

Networked: 45 relevant articles (10 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shailubhai, Kunwar: 6 articles (05/2018 - 11/2015)
2.	Waldman, Scott A: 4 articles (01/2021 - 01/2017)
3.	Miner, Philip B: 4 articles (02/2020 - 01/2017)
4.	Griffin, Patrick H: 3 articles (01/2019 - 01/2017)
5.	Franklin, Howard: 2 articles (01/2022 - 01/2020)
6.	Schoenfeld, Philip: 2 articles (01/2022 - 01/2018)
7.	Shah, Eric D: 2 articles (11/2021 - 01/2018)
8.	Snook, Adam E: 2 articles (01/2021 - 01/2017)
9.	Rappaport, Jeffrey A: 2 articles (10/2020 - 01/2018)
10.	Barish, Charles F: 2 articles (01/2019 - 01/2018)

Related Diseases

1.	Constipation 01/01/2017 - "Plecanatide significantly improved constipation and its related symptoms with a low rate of adverse events. " 09/01/2023 - "Plecanatide was effective in the treatment of severe constipation in adults with CIC or IBS-C." 01/01/2021 - "Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial." 07/01/2018 - "Current treatment paradigm and landscape for the management of chronic idiopathic constipation in adults: Focus on plecanatide." 01/01/2018 - "This multi-center, fixed-dose, open-label study evaluated the long-term safety and tolerability of once-daily oral plecanatide for the treatment of adults with chronic idiopathic constipation (CIC). "
2.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 02/01/2020 - "Plecanatide has been FDA approved as safe and effective for the indications of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C).Areas covered: All clinical trial results supporting approval of plecanatide in IBS-C are reported, evaluated and interpreted in the context of the complex pathophysiology of functional diseases and the barriers that must be overcome for appropriate protocol design and conduct.Expert" 09/01/2023 - "Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation." 01/01/2023 - "Plecanatide Improves Symptoms of Irritable Bowel Syndrome with Constipation: Results of an Integrated Efficacy and Safety Analysis of Two Phase 3 Trials." 01/01/2019 - "Objective: This open-label, multi-center, fixed-dose study (NCT02706483) evaluated the long-term safety and tolerability of plecanatide for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).Methods: Safety and tolerability of once-daily plecanatide 6 mg for up to 53 weeks was assessed in patients with IBS-C who either had been enrolled in one of the phase 3 studies or were study-naïve but met eligibility criteria of the double-blind studies. " 01/01/2018 - "Two identical, phase 3, randomized, double-blind, placebo-controlled trials evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C). "
3.	Diarrhea 01/01/2021 - "Plecanatide is a well-tolerated treatment that relieved the symptoms of CIC with a relatively low incidence of diarrhea." 01/01/2018 - "The rate of treatment-emergent adverse events with plecanatide was low, including rates of diarrhea (5%). " 11/01/2017 - "Plecanatide was well tolerated; the most common AE, diarrhea, occurred in a small number of patients.[ClinicalTrials.gov identifier: NCT02122471]." 01/01/2018 - "FDA publications documented that different definitions for diarrhea were used in linaclotide vs. plecanatide trials. " 01/01/2021 - "Plecanatide is a pH-sensitive uroguanylin analog that increases fluid and ion movement into the gastrointestinal lumen, softening stools and encouraging motility, while limiting the risk of diarrhea. "
4.	Inflammation (Inflammations) 02/06/2017 - "Oral treatment of Apc+/MinFCCC mice with plecanatide produced a statistically significant reduction in the formation of inflammation-driven polypoid, flat and indeterminate dysplasias. " 02/06/2017 - "This study provides the first evidence that orally administered plecanatide reduces the multiplicity of inflammation-driven colonic dysplasia in mice, demonstrating the utility for developing GC-C agonists as chemopreventive agents." 02/06/2017 - "The effect of plecanatide-mediated inhibition of inflammation/dysplasia on endogenous expression of UG and GC-C transcripts was measured in intestinal tissues. " 02/06/2017 - "Taken together, these results suggest that reductions in endogenous UG, accompanied by dysregulation in GC-C signaling, may be an early event in inflammation-promoted colorectal neoplasia; an event that can potentially be ameliorated by prophylactic intervention with plecanatide. " 02/06/2017 - "Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC mice."
5.	Abdominal Pain (Pain, Abdominal) 01/01/2023 - "Significant improvements from baseline in abdominal discomfort, abdominal fullness, abdominal pain, bloating, and cramping occurred as early as Week 1 (Week 2 for abdominal pain) with plecanatide and were maintained through Week 12 versus placebo. " 01/01/2018 - "Plecanatide significantly improved both abdominal pain and constipation symptoms of IBS-C with minimal associated side effects and high levels of tolerability." 01/01/2018 - "In IBS with constipation, plecanatide reduced abdominal pain and increased bowel movements at 12 wk." 10/01/2018 - "New drugs for FBDs (such as lubiprostone, linaclotide, plecanatide, prucalopride, eluxadoline and rifaximin) target key mechanisms in the pathophysiology of these disorders and improve both the abnormal bowel habit and other key symptoms, such as abdominal pain and bloating. "

Related Drugs and Biologics

1.	linaclotide
2.	prucalopride
3.	Lubiprostone
4.	elobixibat
5.	tenapanor
6.	tegaserod (Zelnorm)
7.	TD-5108
8.	ATI 7505
9.	mizagliflozin
10.	Peptides (Polypeptides)

Related Therapies and Procedures

1.	Therapeutics
2.	Chemoprevention